Funds should be able to invest more in promising local innovations, keeping IP in Australia and boosting productivity while generating returns for members.
Last week, French pharmaceutical company Sanofi announced a deal worth over $1 billion to buy a biotech firm with exclusive rights to a unique vaccine technology developed by Australian scientists. This is great news.
The global player will buy into Vicebio, a London-based group, which is developing vaccines for two respiratory viruses using the molecular clamp technology invented by University of Queensland professors Paul Young, Daniel Watterson and Keith Chappell.
